| Market Capitalization (Millions $) |
113 |
| Shares
Outstanding (Millions) |
27 |
| Employees |
23 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-50 |
| Cash Flow (TTM) (Millions $) |
-29 |
| Capital Exp. (TTM) (Millions $) |
0 |
Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of cancer. The company's primary focus is on developing alpha particle immunotherapy, a form of targeted radiation therapy that selectively targets cancer cells while minimizing damage to healthy tissue.
Actinium has developed a proprietary technology called Actinium-225/Bismuth-213 Generator (ABG) which is used to produce isotopes that can be used in targeted alpha particle therapy. The company is working on developing multiple drug candidates based on this technology, which can target a range of cancers including acute myeloid leukemia, multiple myeloma, and non-Hodgkin's lymphoma.
One of the most promising drug candidates is Iomab-B, which is designed to target patients with relapsed/refractory acute myeloid leukemia (AML). The drug works by targeting the CD45 antigen found on the surface of leukemic cells and delivering a lethal dose of radiation. Iomab-B has shown promising results in clinical trials, with a 100% complete remission rate in patients who received a transplant following treatment.
Actinium is also involved in the development of a series of other drug candidates, including Actimab-A, Actimab-M, and Actimab-MDS. These drugs are designed to target other forms of cancer, including multiple myeloma and myelodysplastic syndrome.
The company has established collaborations with a number of other organizations, including Memorial Sloan-Kettering Cancer Center, Fred Hutchinson Cancer Research Center, and the National Cancer Institute. These collaborations allow Actinium to access the expertise of world-renowned scientists and clinicians, as well as access to patient populations for clinical trials.
Actinium has a strong management team with extensive experience in the biopharmaceutical industry. The company is led by Sandesh Seth, who joined Actinium as CEO in 201 Prior to joining Actinium, Seth worked in various executive positions at Vela Pharmaceuticals, Celgene Corporation, and Sun Pharmaceuticals. The company has also attracted a team of experienced scientists and researchers, with expertise in nuclear medicine, radiochemistry, and drug development.
In summary, Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of cancer. The company is at the forefront of developing alpha particle immunotherapy, a form of targeted radiation therapy, and has a number of promising drug candidates in development, including Iomab-B, Actimab-A, Actimab-M, and Actimab-MDS. The company has established collaborations with world-renowned institutions and has a strong management team and a team of experienced scientists and researchers.
Company Address: 275 Madison Avenue, 7th Fl New York 10016 NY
Company Phone Number: 677-3870 Stock Exchange / Ticker: NYSE ATNM
| ATNM is expected to report next financial results on March 30, 2024. |
|
|
